key: cord-0930071-t3gck42o
authors: Jhamb, S; Khan, S; Taneja, H; Sachdev, A; Mazumder, D; Buikema, A
title: POSB33 Comorbidities, Oxygen Therapy Use and Rehospitalization in US Patients with Severe COVID-19
date: 2022-01-31
journal: Value in Health
DOI: 10.1016/j.jval.2021.11.143
sha: 4d17c031a542e3035d1eb75926c2db223af066f6
doc_id: 930071
cord_uid: t3gck42o

Objectives: Oxygen therapy is critical in severe COVID-19 patients. Factors that impact the oxygen use in severe COVID-19 patients are important to understand. This study aims to identify the factors such as co-morbidities, length of stay, post-discharge oxygen use, and rehospitalization in COVID-19 patients with oxygen therapy. Methods: We identified hospitalized patients diagnosed with COVID-19 from 01 April 2020 to 31 December 2020 using Optum’s de-identified US administrative claims database. Index date was date of first inpatient COVID-19 diagnosis. Included patients had evidence of oxygen therapy during their hospital stay;pregnant patients were excluded. Patients were observed 12-months pre-index to capture demographics and comorbidities;and were observed for at least 3 months post-discharge to assess the outcomes. Results: A total of 104,456 hospitalized patients with COVID-19 were identified;16,492 (15.8%) had evidence of oxygen therapy use during hospitalization. Mean (SD) age was 68.8 (12.1) years, 48.3% were males. During baseline, the most frequent (top 5) comorbidities were hypertension (83.7%), other cardiovascular disease (69.5%), diabetes mellitus (52.2%), obesity (51.7%), and kidney disease (38.7%). Respiratory-related comorbidities such as COPD, other pulmonary disease, and asthma were found in 34.0%, 32.9%, and 16.0% of patients, respectively. Hospital length of stay was <7 days, 7-14 days and >14 days for 30.6%, 29.1%, and 17.8% of patients, respectively;5.0% of patients had evidence of home-based oxygen therapy after discharge. Overall, 28.3% of patients were rehospitalized within 60 days post-discharge regardless of their home-based oxygen use. Conclusions: Comorbidities were prevalent among hospitalized patients with COVID-19 using oxygen therapy;and rehospitalization was common. Further analysis is needed to understand the impact of comorbid conditions on rehospitalization in patients with severe COVID-19 requiring hospitalization and oxygen therapy. Evidence of oxygen therapy was low, suggesting oxygen use is under-reported in administrative claims data, future studies using EHR data may be appropriate.

IN, USA, 3 Eli Lilly and Company, Sydney, NSW, Australia Objectives: Connected insulin pen systems may improve outcomes in insulintreated people with diabetes (PwD), potentially reducing disease burden and improving suboptimal insulin use. Within this rapidly developing field, a systematic literature review (SLR) was conducted to summarise the current clinical, economic, and patient-reported benefits of this technology. Methods: A systematic search of Medline, Embase and Cochrane library databases (limits: randomised controlled trials [RCTs] , observational studies, and economic models; publication date, 2015-2021; English-language), select conference proceedings (limits: 2018-2021), US and European clinical trial registries, and the grey literature (no limits) was performed following PRISMA guidelines. Subjects were Type 1 and 2 adult PwD. Technologies assessed included: connected insulin pens/systems, insulin smart caps/sleeves, and associated mobile applications. Results: 1,898 publications/abstracts were identified. Following screening, 11 unique studies were retained for analysis: 6 observational studies, three RCTs and two economic studies. The small size and observational design of many studies, as well as heterogeneity of outcomes, precludes drawing firm overall conclusions. However, the emerging data show a positive trend for the impact of connected insulin pens on PwD. Specifically, use of connected technologies resulted in fewer missed bolus doses, better time in range and blood glucose levels, lower incidence of hypoglycaemia, higher patient satisfaction, and lower costs.

Conclusions: This SLR documented that connected insulin pen systems may help to reduce suboptimal insulin dosing. Studies demonstrate that these systems may help type 1 and type 2 PwDs to relieve the burden of insulin-treatment and to reduce the number of missed bolus injections, which leads to better glycaemic control. Although evidence in this field is still in its early stages, early indications suggest that connected insulin pen systems could be increasingly considered as part of routine clinical care for insulin-treated PwD who are faced with the complexity of their daily insulin routine.

Jimenez R, Cicero S, Bron M, Shah C, Angelov AS Neurocrine Biosciences, Inc., San Diego, CA, USA Objectives: Once-daily valbenazine is approved for tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to dopamine receptor blocking agents (e.g., antipsychotics). This Phase 4, double-blind, placebo-controlled, withdrawal study (NCT03891862) was conducted to assess the persistence of valbenazine effect in patients with TD. Methods: Study participants received open-label valbenazine (VBZ-OL) for 8 weeks, with dosing initiated at 40 mg and escalated to 80 mg after 1 week (dose reduction allowed for tolerability). After VBZ-OL, participants were randomized (1:1) to receive placebo (VBZ/PBO) or continue taking the same valbenazine dose (VBZ/VBZ). Assessments were conducted at study baseline, Week 8 (end of VBZ-OL, randomization baseline), and Week 16 (end of withdrawal). Abnormal Involuntary Movement Scale (AIMS) total score was used to assess persistence of effect. Patient-reported outcomes included EuroQoL's 5-Dimension 5-Level questionnaire (EQ-5D-5L) and the Sheehan Disability Scale (SDS). Mean values are presented with standard errors. Results: Persistence of effect was analyzed in 117 randomized participants (pla-cebo=58; valbenazine=59). Mean changes from study baseline to Week 8 in AIMS total score indicated improvements with VBZ-OL. Changes from Week 8 to Week 16 indicated initial loss of valbenazine effect after treatment withdrawal: VBZ/PBO, 0.760.7; VBZ/VBZ, -1.760.4. However, mean changes from study baseline to Week 16 suggested some overall persistence of valbenazine effect: VBZ/PBO, -3.260.7; VBZ/ VBZ, -5.560.6. Mean improvements from study baseline to Week 16 for healthrelated quality of life (EQ-5D-5L) and functional status (SDS) were greater in patients who continued taking valbenazine. 32.6% of all participants had $1 TEAE with VBZ-OL; 32.2% (VBZ/PBO) and 23.7% (VBZ/VBZ) had $1 TEAE during randomized withdrawal. Conclusions: Valbenazine effects diminished after treatment withdrawal, but some overall persistence of effect was observed. Overall mean improvements in TD movements, quality of life, and functioning were greater in patients who continued receiving once-daily valbenazine.

Jhamb S, 1 Khan S, 1 Taneja H, 1 Sachdev A, 1 Mazumder D, 1 Buikema A 2 1 Optum Global Solutions, Noida, India, 2 Optum HEOR, Eden Prairie, MN, USA Objectives: Oxygen therapy is critical in severe COVID-19 patients. Factors that impact the oxygen use in severe COVID-19 patients are important to understand. This study aims to identify the factors such as co-morbidities, length of stay, post-discharge oxygen use, and rehospitalization in COVID-19 patients with oxygen therapy. Methods: We identified hospitalized patients diagnosed with COVID-19 from 01 April 2020 to 31 December 2020 using Optum's de-identified US administrative claims database. Index date was date of first inpatient COVID-19 diagnosis. Included patients had evidence of oxygen therapy during their hospital stay; pregnant patients were excluded. Patients were observed 12-months pre-index to capture demographics and comorbidities; and were observed for at least 3 months postdischarge to assess the outcomes. Results: A total of 104,456 hospitalized patients with COVID-19 were identified; 16,492 (15.8%) had evidence of oxygen therapy use during hospitalization. Mean (SD) age was 68.8 (12.1) years, 48.3% were males. During baseline, the most frequent (top 5) comorbidities were hypertension (83.7%), other cardiovascular disease (69.5%), diabetes mellitus (52.2%), obesity (51.7%), and kidney disease (38.7%). Respiratory-related comorbidities such as COPD, other pulmonary disease, and asthma were found in 34.0%, 32.9%, and 16.0% of patients, respectively. Hospital length of stay was ,7 days, 7-14 days and .14 days for 30.6%, 29.1%, and 17.8% of patients, respectively; 5.0% of patients had evidence of homebased oxygen therapy after discharge. Overall, 28.3% of patients were rehospitalized within 60 days post-discharge regardless of their home-based oxygen use. Conclusions: Comorbidities were prevalent among hospitalized patients with COVID-19 using oxygen therapy; and rehospitalization was common. Further analysis is needed to understand the impact of comorbid conditions on rehospitalization in patients with severe COVID-19 requiring hospitalization and oxygen therapy. Evidence of oxygen therapy was low, suggesting oxygen use is under-reported in administrative claims data, future studies using EHR data may be appropriate. Results: A total of 18 studies from 166 publications met the inclusion criteria of the review. No head-to-head trials of single-inhaler triple therapy (SITT) have been performed yet. Triple therapy resulted in the significant reduction of the annual rate of moderate or severe exacerbations in a rate ratio of 0.48-0.85 compared with LAMA/LABA, 0.58-0.77 compared to LABA/ICS and 0.80 compared to LAMA. Additionally, triple therapy significantly improved lung function (p,0.05) along with reducing St. George's Respiratory Questionnaire (SGRQ) score, which is a preferred measurement of COPD control. Regarding mortality, a reduced risk of all-cause mortality in patients treated with triple therapy versus LAMA/LABA had been demonstrated. Conclusions: The findings of the current review showed that triple therapy is effective in the management of COPD and was associated with a significant reduction of moderate-to-severe COPD exacerbations, improved lung function and improved quality of life when compared to dual single-inhaler therapy. 

To systematically review and summarize the real-world evidence for epidemiology, patient characteristics, treatments, clinical and economic outcomes of psoriasis in Mainland China and Taiwan. Methods: English (MEDLINE, EMBASE, Web of Sciences, and The Cochrane Library) and Chinese databases (WANFANG, CNKI, and VIP) were searched for relevant real

Psoriasis Area and Severity Index (PASI: 16.1 vs. 16.2), and quality of life measured by time trade-off (0.649 vs. 0.744). In patients with moderate-to-severe psoriasis, 29.9% used biologics in China and 78.4% in Taiwan. The treatment discontinuation rate of systemic therapy (including oral, intravenous, and subcutaneous administration treatments) was 63.6% in China and 64

0% at 13 th month vs. 47.6% at 6 th month) and ustekinumab (PASI-90: 30.3% at 7 th month vs. 27.3% at 4 th month), didn't further improve treatment outcomes. Patients with moderate-to-severe psoriasis who used biologics had higher hospital costs per episode in China (U16,372 vs. U7,461) and higher annual medical